The review, conducted by a team of researchers led by Abhinav Janappareddi of the University of Washington School of Medicine, systematically combed the medical literature through PubMed and Scopus to identify every study that had reported outcomes for hidradenocarcinoma treated with Mohs micrographic surgery. The search identified seven studies published between 2004 and 2021, and from those studies the team extracted eighteen documented cases in which patients with hidradenocarcinoma underwent the Mohs procedure. The headline finding is striking: across all eighteen cases, the authors found no reported recurrences and no reported metastases during follow-up.

To appreciate why that number matters, it helps to understand what the conventional alternative achieves. Wide local excision, the most commonly reported treatment for hidradenocarcinoma, removes the visible tumor together with a predetermined margin of surrounding tissue, typically several centimeters in every direction. The excised specimen is then examined by a pathologist, who checks whether the margins are free of tumor. Recurrence rates for hidradenocarcinoma treated this way range from 10 to 50 percent in the published literature, a spread that reflects both the biology of the tumor and the difficulty of ensuring that invisible fingerlike extensions of cancer have been completely removed.

Mohs micrographic surgery takes the opposite approach to margin control. Instead of removing a fixed block of tissue and waiting for pathology results, the Mohs surgeon removes the tumor in thin layers. Each layer is immediately frozen, sectioned, stained, and examined under the microscope while the patient waits in the office. The microscope is used to map exactly where tumor cells remain, and only those specific areas are excised in the next layer. The process repeats until every margin is microscopically clear. The result is a surgical technique that achieves complete margin assessment, rather than the sampling assessment that conventional pathology provides, while sparing as much healthy tissue as possible.

That tissue-sparing quality is particularly valuable for hidradenocarcinoma because of where these tumors tend to appear. The review notes that cases have arisen on the scalp, the forehead, the nose, the vulva, and the abdominal wall, sites where wide excision can be disfiguring or technically challenging. One of the studies included in the review described the challenge of treating hidradenocarcinoma on a rhinophymatous nose, where distorted anatomy made histologic interpretation genuinely difficult, a situation the authors of that report called a histologic conundrum. Another described a multidisciplinary approach combining Mohs surgery with other specialties to manage a hidradenocarcinoma of the scalp. In each of these scenarios, the ability to trace tumor extensions microscopically, layer by layer, offers a rational advantage over removing a large fixed margin and hoping it was enough.

The biology of hidradenocarcinoma helps explain why margin control is so critical. The tumor is known by several names in the literature, including malignant hidradenoma, malignant acrospiroma, clear cell eccrine carcinoma, and primary mucoepidermoid cutaneous carcinoma, reflecting a long history of debate about its exact classification. What unites these labels is that the tumor arises from the eccrine or apocrine sweat duct apparatus and behaves with a propensity for local infiltration and, in a meaningful minority of cases, metastasis to lymph nodes and distant organs. Reported cases in the broader literature describe patients requiring surgery combined with chemotherapy for metastatic disease, or wide excision plus adjuvant radiotherapy for tumors of the trunk. Against that backdrop, a surgical series with zero recurrences is not a trivial statistical curiosity but a signal worth investigating.

The authors of the review are careful, appropriately, not to overclaim. Eighteen cases spread across seven studies is a small foundation, and the studies themselves are largely case reports and small case series, the weakest tier of the clinical evidence hierarchy. Patients were not randomized to Mohs surgery versus wide local excision, follow-up durations varied, and publication bias likely favors the reporting of successful outcomes. The authors explicitly state that the generalizability of current findings is limited by the existing literature, and they frame their result not as a practice-changing conclusion but as a call for larger, controlled studies to better define the role of Mohs micrographic surgery in hidradenocarcinoma management, whether as a sole treatment or in combination with adjunct therapies such as sentinel lymph node mapping or radiotherapy.

That caution is consistent with how the field has historically handled ultra-rare tumors. When a cancer is so uncommon that no single institution can accumulate a meaningful series, the evidence base is built case by case, and narrative reviews like this one serve as the mechanism for aggregating scattered experience into something approaching a signal. The Mayo Clinic experience included in the review, covering Mohs treatment of hidradenocarcinoma from 1993 to 2013, represents one of the largest single-institution contributions, and even it contributed only a handful of cases. A more recent case series from Scripps Clinic, published in 2024, similarly combined institutional experience with a systematic review of the literature, underscoring how slowly the evidence accumulates for a tumor that most dermatologists may see once, if ever, in a career.

For clinicians, the practical takeaway is nuanced. Wide local excision remains the most commonly reported and most widely accepted treatment, and no guideline currently recommends replacing it with Mohs surgery on the strength of eighteen cases. But the review gives surgeons treating a hidradenocarcinoma in a cosmetically or functionally sensitive location, such as the face, scalp, or genital skin, a documented body of experience supporting Mohs micrographic surgery as a reasonable alternative, particularly when the goal is complete microscopic margin control without sacrificing large amounts of tissue. It also reinforces the importance of long-term surveillance regardless of the surgical approach, because even the most optimistic case series cannot yet rule out late recurrences or metastases.

For patients, the message is one of cautious optimism. A cancer that has historically recurred in as many as half of treated cases may, in the documented experience of Mohs surgery to date, have been cured in every reported instance. That gap between 10 to 50 percent recurrence and zero recurrences is exactly the kind of discrepancy that motivates the larger, controlled studies the authors are calling for. Until those studies exist, the eighteen patients whose outcomes form the backbone of this review represent both the best evidence available and a compelling argument that the microscope, used layer by layer in the operating room, may deserve a larger role in the fight against one of dermatology’s rarest and most feared tumors.

Subject of Research: Treatment of hidradenocarcinoma with Mohs micrographic surgery

Article Title: Hidradenocarcinoma: a narrative review of treatment with Mohs micrographic surgery

Article References: Janappareddi, A., Kamineni, D. P., Kaur, P., Collins, C. L., Almatroud, L., Verzosa, M. S., Oh, A., Sanka, S. A., Kooner, A., Wan, L., Bondugula, N., & Engledow, E. (2026). Hidradenocarcinoma: a narrative review of treatment with Mohs micrographic surgery. Archives of Dermatological Research, 318(1), Article 466. https://doi.org/10.1007/s00403-026-04955-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04955-3

Keywords: hidradenocarcinoma, Mohs micrographic surgery, wide local excision, sweat gland cancer, eccrine carcinoma, dermatologic surgery, cancer recurrence, skin cancer, narrative review, adjuvant therapy, dermatology, malignant acrospiroma